We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives.
- Authors
Karachaliou, Niki; Bruno, Manuel Fernandez; Bracht, Jillian Wilhelmina Paulina; Rosell, Rafael
- Abstract
Discovered in 2007, anaplastic lymphoma kinase (ALK) gene rearrangements positive (ALK+) lung cancers compose a small subset of non-small cell lung cancer (NSCLC), with rapidly expanded treatments. There are currently several ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib which have been licensed by the US Food and Drug Administration or the European Medicines Agency for the treatment of ALK+ NSCLC patients. Along with the multiple therapies, the survival of this subtype of NSCLC has been significantly expanded, even for patients whose disease has spread in the brain. Alectinib (Alecensa), a specific ALK and rearranged during transfection tyrosine kinase inhibitor is approved as first-line therapy for metastatic ALK+ NSCLC patients. It is additionally approved for ALK+ NSCLC previously treated with crizotinib. The main aim of this review is to assemble on the efficacy of alectinib for the treatment of ALK+ NSCLC, to elaborate the activity of the drug in the central nervous system, and to debate on which is the position of this compound in the treatment course of ALK+ lung cancer patients.
- Subjects
EUROPEAN Medicines Agency; NON-small-cell lung carcinoma; UNITED States. Food &; Drug Administration; ANAPLASTIC lymphoma kinase; PATIENT selection; LUNG cancer; CENTRAL nervous system
- Publication
OncoTargets & Therapy, 2019, Vol 12, p4567
- ISSN
1178-6930
- Publication type
Article
- DOI
10.2147/OTT.S174548